Aligos Therapeutics Statistics
Total Valuation
ALGS has a market cap or net worth of $40.98 million. The enterprise value is -$31.61 million.
Important Dates
The last earnings date was Thursday, March 5, 2026, before market open.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALGS has 6.15 million shares outstanding. The number of shares has increased by 57.79% in one year.
| Current Share Class | 5.35M |
| Shares Outstanding | 6.15M |
| Shares Change (YoY) | +57.79% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 1.85% |
| Owned by Institutions (%) | 29.31% |
| Float | 3.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.75 |
| Forward PS | 22.32 |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.90, with a Debt / Equity ratio of 0.10.
| Current Ratio | 3.90 |
| Quick Ratio | 3.67 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -196.92% and return on invested capital (ROIC) is -287.93%.
| Return on Equity (ROE) | -196.92% |
| Return on Assets (ROA) | -69.33% |
| Return on Invested Capital (ROIC) | -287.93% |
| Return on Capital Employed (ROCE) | -130.74% |
| Weighted Average Cost of Capital (WACC) | 17.17% |
| Revenue Per Employee | $31,229 |
| Profits Per Employee | -$345,614 |
| Employee Count | 70 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ALGS has paid $314,000 in taxes.
| Income Tax | 314,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.56% in the last 52 weeks. The beta is 2.75, so ALGS's price volatility has been higher than the market average.
| Beta (5Y) | 2.75 |
| 52-Week Price Change | -53.56% |
| 50-Day Moving Average | 8.08 |
| 200-Day Moving Average | 8.60 |
| Relative Strength Index (RSI) | 40.29 |
| Average Volume (20 Days) | 40,260 |
Short Selling Information
The latest short interest is 288,715, so 4.69% of the outstanding shares have been sold short.
| Short Interest | 288,715 |
| Short Previous Month | 293,582 |
| Short % of Shares Out | 4.69% |
| Short % of Float | 8.01% |
| Short Ratio (days to cover) | 4.09 |
Income Statement
In the last 12 months, ALGS had revenue of $2.19 million and -$24.19 million in losses. Loss per share was -$2.45.
| Revenue | 2.19M |
| Gross Profit | 2.19M |
| Operating Income | -87.99M |
| Pretax Income | -23.88M |
| Net Income | -24.19M |
| EBITDA | -87.06M |
| EBIT | -87.99M |
| Loss Per Share | -$2.45 |
Full Income StatementBalance Sheet
The company has $77.84 million in cash and $5.25 million in debt, with a net cash position of $72.59 million or $11.80 per share.
| Cash & Cash Equivalents | 77.84M |
| Total Debt | 5.25M |
| Net Cash | 72.59M |
| Net Cash Per Share | $11.80 |
| Equity (Book Value) | 53.55M |
| Book Value Per Share | 8.67 |
| Working Capital | 61.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$82.50 million and capital expenditures -$437,000, giving a free cash flow of -$82.94 million.
| Operating Cash Flow | -82.50M |
| Capital Expenditures | -437,000 |
| Free Cash Flow | -82.94M |
| FCF Per Share | -$13.48 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -4,024.93% |
| Pretax Margin | -1,092.36% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALGS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -57.79% |
| Shareholder Yield | -57.79% |
| Earnings Yield | -59.03% |
| FCF Yield | -202.38% |
Analyst Forecast
The average price target for ALGS is $46.67, which is 600.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.67 |
| Price Target Difference | 600.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 174.64% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 19, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Aug 19, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |
